[Federal Register Volume 61, Number 96 (Thursday, May 16, 1996)]
[Notices]
[Pages 24813-24814]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 96-12272]



-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE
[DEA # 147F]


Controlled Substances: 1996 Aggregate Production Quotas

AGENCY: Drug Enforcement Administration (DEA), Justice.

ACTION: Notice of final revised 1996 aggregate production quotas.

-----------------------------------------------------------------------

SUMMARY: The interim notice (61 FR 14336, April 1, 1996) which 
established revised 1996 aggregate production quotas for amobarbital 
and hydromorphone, Schedule II controlled substances, as required under 
the Controlled Substances Act (CSA) (21 U.S.C. 826), is adopted without 
change.

DATES: This order is effective on May 16, 1996.

FOR FURTHER INFORMATION CONTACT: Howard McClain, Jr., Chief, Drug and 
Chemical Evaluation Section, Drug Enforcement Administration, 
Washington, DC 20537, (202) 307-7183.

SUPPLEMENTARY INFORMATION: Section 306 of the Controlled Substances 
Act, (21 U.S.C. 826), requires the Attorney General to establish 
aggregate production quotas for controlled substances in Schedules I 
and II each year. This responsibility has been delegated to the 
Administrator of the DEA pursuant to Section 0.100 of Title 28 of the 
Code of Federal Regulations. The Administrator in turn, has redelegated 
this function to the Deputy Administrator of the DEA pursuant to

[[Page 24814]]

Section 0.104 of Title 28 of the Code of Federal Regulations.
    On April 1, 1996, an interim notice establishing revised 1996 
aggregate production quotas for amobarbital and hydromorphone was 
published in the Federal Register (61 FR 11063). All interested persons 
were invited to comment on or object to these proposed aggregate 
production quotas on or before May 1, 1996. Since no comments or 
objections were received, the interim notice is adopted without change.
    The Office of Management and Budget has determined that notices of 
aggregate production quotas are not subject to centralized review under 
Executive Order 12866. This action has been analyzed in accordance with 
the principles and criteria contained in Executive Order 12612, and it 
has been determined that this matter does not have sufficient 
federalism implications to warrant the preparation of a Federalism 
Assessment.
    The Deputy Administrator hereby certifies that this action will 
have no significant impact upon small entities whose interests must be 
considered under the Regulatory Flexibility Act, 5 U.S.C. 601, et seq. 
The establishment of annual aggregate production quotas for Schedules I 
and II controlled substances is mandated by law and by international 
treaty obligations. While aggregate production quotas are of primary 
importance to large manufacturers, their impact upon small entities is 
neither negative nor beneficial. Accordingly, the Deputy Administrator 
has determined that this action does not require a regulatory 
flexibility analysis.
    Therefore, under the authority vested in the Attorney General by 
Section 306 of the Controlled Substances Act of 1970 (21 U.S.C. 826), 
delegated to the Administrator of the DEA by Section 0.100 of Title 28 
of the Code of Federal Regulations, and redelegated to the Deputy 
Administrator, pursuant to Section 0.104 of Title 28 of the Code of 
Federal Regulations, the Deputy Administrator hereby orders that the 
revised 1996 aggregate production quotas for the listed controlled 
substances, expressed in grams of anhydrous acid or base, be 
established as follows:

------------------------------------------------------------------------
                                                            Established 
                       Basic class                         revised 1996 
                                                               quota    
------------------------------------------------------------------------
Amobarbital.............................................         301,000
Hydromorphone...........................................         718,000
------------------------------------------------------------------------

    Dated: May 9, 1996.
Stephen H. Greene,
Deputy Administrator.
[FR Doc. 96-12272 Filed 5-15-96; 8:45 am]
BILLING CODE 4410-09-M